Woodmont Investment Counsel’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Woodmont Investment Counsel’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-100	Closed	-$9.49K	–	369
2024 Q1	$9.49K	Buy	+100	New	+$9.28K	﹤0.01%	334
2016 Q4	–	Sell	-250	Closed	-$17K	–	625
2016 Q3	$17K	Buy	+250	New	+$15.5K	﹤0.01%	390
2016 Q2	–	Sell	-150	Closed	-$8K	–	458
2016 Q1	$8K	Hold	150	–	–	﹤0.01%	436
2015 Q4	$11K	Hold	150	–	–	﹤0.01%	421
2015 Q3	$9K	Buy	+150	New	+$11.8K	﹤0.01%	434

Other funds holding XBI

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Woodmont Investment Counsel's XBI Position: Q2 2024 in Review

Woodmont Investment Counsel sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 100 shares — an estimated $9.49K sold.

Woodmont Investment Counsel first reported a position in XBI in Q3 2015 and held it in 5 quarters. The position peaked at $17K in Q3 2016. 761 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

Woodmont Investment Counsel reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
Woodmont Investment Counsel sold 100 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $9.49K.
Woodmont Investment Counsel first reported a position in State Street SPDR S&P Biotech ETF in Q3 2015 and held it in 5 quarters.
Woodmont Investment Counsel's State Street SPDR S&P Biotech ETF position peaked at $17K in Q3 2016.
761 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Woodmont Investment Counsel's 13F filing for Q2 2024, filed 18 Jul 2024.